Biomarkers and Translational Tools (BTT) Community

Community Goals

Scientific Expertise: 
  • The Biomarkers and Translational Tools (BTT) Community facilitates interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.
Catalyst for Innovation: 
  • The BTT Community is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on biomarker and translational tools.  
Influence and Impact
  • The BTT Community is the lead group engaged in promoting the use of biomarkers and other translational tools for optimizing drug development and patient care.
Education and Communication: 
  • The BTT Community offers educational opportunities via the Annual Meeting and other fora.
Organizational Effectiveness: 
  • Leadership within BTT will be expanded by establishing a Network Steering Committee.  
  • The BTT Community has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
  • The BTT Community fosters the career of its members by assisting in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programs, and providing opportunities for networking activities throughout an individual’s career.   
Community News
Please log in as a member to access more Community News and members-only content.

Community Webinar
Title: Model-Informed Biomarker Qualification, Presented by the BTT Community
Date and Time: Thursday, January 18, 2018, 12:00 pm ET
Moderator: Ana Caroline Costa Sa, Target Sciences, GSK
Speakers: Daniela J. Conrado, PhD, Associate Director, Quantitative Medicine, Critical Path Institute; Jackson Burton, PhD, Associate Program Director, Quantitative Medicine, Critical Path Institute
Description: The Alzheimer (Coalition Against Major Diseases) and the Parkinson (Critical Path for Parkinson’s) consortia at the Critical Path Institute (C-Path) are pursuing regulatory qualification of enrichment biomarkers that select subjects most likely to exhibit clinically relevant disease progression. Pharmacometric analyses have been conducted to examine clinical trial enrichment utility of intracranial adjusted hippocampal volume for mild cognitive impairment, and dopamine transporter neuroimaging for early stage Parkinson disease. 
This presentation will: (a) review different biomarker categories and their role in drug development; (b) review the process to qualify a biomarker and the role of collaborative efforts; (c) present two case studies in neuroscience (Parkinson and Alzheimer disease). 
Registration Link:

Joint Systems Pharmacology and Biomarkers & Translational Tools Community Webinar
: Quantitative Systems Pharmacology (QSP) Modeling of Drug-Induced Nephrotoxicity – Bridging the Link Between Drug Exposure, Urinary Biomarkers and Renal Dysfunction, Presented by the BTT and SP Communities
Date and Time: Friday, February 16, 2018, 12:00 pm ET
Speakers: Yeshitila Gebremichael, PhD, Scientist, DILIsym Services., Inc.
Moderators: Richard Graham, PhD, Senior Director, Theravance Biopharma and BTT Community Chair
Description: Drug-induced nephrotoxicity is a challenging problem in both drug development and clinical treatment of critically ill patients. Detecting the potential for nephrotoxicity early in the drug development process is vital for safe development and dosing of therapies. Many novel urinary biomarkers that are injury-specific and more sensitive than traditional biomarkers have been identified recently, whereas interpretation remains challenging. Furthermore, a quantitative framework that links biomarkers signals to underlying cellular injury and renal dysfunction is lacking. Such framework plays a crucial role in safe drug development and clinical treatment. By coupling observations from preclinical urinary biomarkers and histopathology data with cell biology, renal physiology, and the physiologic processes involved in biomarker expression, we developed a multiscale quantitative systems pharmacology (QSP) model of drug-induced acute kidney injury.
Registration Link:

Past Webinars
Prediction of Clinical Outcome After 4 & 8 Weeks of Citalopram/Escitalopram Therapy for Major Depression: A Data-Driven Machine Learning Approach
528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |